C. Cheng

Long-term remission in multiply relapsed enteropathy-associated T-cell lymphoma following CD30 CAR T-cell therapy.

J. Serody, A. Ivanova, N. Ghosh, 2020, Blood advances.

Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma.

J. Serody, A. Ivanova, H. Heslop, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pretherapy metabolic tumor volume is associated with response to CD30 CAR T cells in Hodgkin lymphoma

J. Serody, A. Ivanova, A. Khandani, 2021, Blood advances.

Utility of Safety Switch to Abrogate CD19.CAR T Cell-Associated Neurotoxicity.

J. Serody, A. Ivanova, J. Coghill, 2021, Blood.

CD30-Directed CAR-T Cells Co-Expressing CCR4 in Relapsed/Refractory Hodgkin Lymphoma and CD30+ Cutaneous T Cell Lymphoma

J. Serody, A. Ivanova, B. Savoldo, 2021, Blood.

Infusion of CD30 CAR T Cells Is Safe and Effective As Consolidation Following Autologous Hematopoietic Stem Cell Transplant

J. Serody, A. Ivanova, T. Shea, 2021, Transplantation and Cellular Therapy.

Effect of long term imatinib on bone in adults with chronic myelogenous leukemia and gastrointestinal stromal tumors.

R. Maki, M. Fleisher, G. Heller, 2013, Leukemia research.

A Phase Ib/II Study of Anti-CD30 Chimeric Antigen Receptor T Cells for Relapsed/Refractory CD30+ Lymphomas

J. Serody, A. Ivanova, T. Shea, 2019, Biology of Blood and Marrow Transplantation.

Clinical Responses to CAR.CD30-T Cells in Patients with CD30+ Lymphomas Relapsed after Multiple Treatments Including Brentuximab Vedotin

J. Serody, A. Ivanova, T. Shea, 2018, Blood.

A phase 1b/2 study of CD30-specific chimeric antigen receptor T-cell (CAR-T) therapy in combination with bendamustine in patients with CD30+ Hodgkin and non-Hodgkin lymphoma.

J. Serody, A. Ivanova, T. Shea, 2017 .

Effects of Long Term Imatinib on Bone Mineral Density In Patients with Chronic Myelogenous Leukemia (CML) or Gastrointestinal Stromal Tumor (GIST)

R. Maki, M. Fleisher, H. Strauss, 2010 .